Cencora, Inc. (COR) EV/EBITDA Ratio: 13.05x
Is Cencora, Inc.’s EV/EBITDA ratio high or low?
Cencora, Inc.'s EV/EBITDA ratio of 13.05x is in line with its 5-year average of 13.89x, around the middle of its 5-year range (9.57x–21.15x).
As of Saturday, June 13, 2026. 25.19% below its 12-month average of 17.44x.
COR EV/EBITDA Ratio Chart
COR Average EV/EBITDA Ratio Chart
COR Current vs Average EV/EBITDA Ratio Chart
COR EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
13.05x
EV/EBITDA RATIO AVG TTM
17.44x
EV/EBITDA RATIO AVG 3Y
15.28x
EV/EBITDA RATIO AVG 5Y
13.89x
EV/EBITDA RATIO AVG 10Y
13.19x
EV/EBITDA RATIO AVG 15Y
13.84x
EV/EBITDA RATIO AVG 20Y
12.57x
CURRENT VS TTM AVG
-25.19%
CURRENT VS 3Y AVG
-14.60%
CURRENT VS 5Y AVG
-6.07%
CURRENT VS 10Y AVG
-1.07%
CURRENT VS 15Y AVG
-5.71%
CURRENT VS 20Y AVG
+3.79%
COR Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cencora, Inc. (COR) | $54.80B | 13.05x | 17.44x | 15.28x | 13.89x |
| Becton, Dickinson and Company (BDX) | $52.98B | 13.81x | 12.76x | 14.60x | 15.15x |
| Regeneron Pharmaceuticals, Inc. (REGN) | $63.06B | 11.43x | 12.74x | 17.18x | 14.74x |
| Humana Inc. (HUM) | $45.53B | 19.22x | 11.76x | 11.35x | 12.38x |
| IDEXX Laboratories, Inc. (IDXX) | $44.24B | 30.34x | 35.72x | 34.45x | 38.21x |
| Agilent Technologies, Inc. (A) | $36.67B | 19.58x | 21.07x | 21.68x | 23.09x |
| Zoetis Inc. (ZTS) | $33.36B | 10.15x | 15.60x | 20.66x | 23.73x |
| Centene Corporation (CNC) | $32.19B | N/A | 4.99x | 7.28x | 9.49x |
| Medline Inc. (MDLN) | $30.96B | 14.84x | 16.17x | 16.17x | 16.17x |
| Cigna Corporation (CI) | $78.83B | 8.41x | 8.34x | 9.18x | 9.49x |
EV/EBITDA vs. its own history
At 13.1, EV/EBITDA is in its normal range, sitting higher than 63% of its 20-year history.
20-year low
5.3
median
11.8
20-year high
32.7
Cencora, Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Cencora, Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Cencora, Inc. (COR)?
- The EV/EBITDA ratio for COR stock is 13.05x.
- Is Cencora, Inc.'s EV/EBITDA ratio high or low?
- Cencora, Inc.'s EV/EBITDA ratio of 13.05x is in line with its 5-year average of 13.89x, around the middle of its 5-year range (9.57x–21.15x).
- What is the TTM average EV/EBITDA ratio for Cencora, Inc. (COR)?
- The TTM average EV/EBITDA ratio for COR stock is 17.44x.
- What is the 3Y average EV/EBITDA ratio for Cencora, Inc. (COR)?
- The 3Y average EV/EBITDA ratio for COR stock is 15.28x.
- What is the 5Y average EV/EBITDA ratio for Cencora, Inc. (COR)?
- The 5Y average EV/EBITDA ratio for COR stock is 13.89x.
- What is the 10Y average EV/EBITDA ratio for Cencora, Inc. (COR)?
- The 10Y average EV/EBITDA ratio for COR stock is 13.19x.
- What is the 15Y average EV/EBITDA ratio for Cencora, Inc. (COR)?
- The 15Y average EV/EBITDA ratio for COR stock is 13.84x.
- What is the 20Y average EV/EBITDA ratio for Cencora, Inc. (COR)?
- The 20Y average EV/EBITDA ratio for COR stock is 12.57x.
Cencora, Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-12 | 13.05x |
| 2026-06-11 | 13.04x |
| 2026-06-10 | 13.03x |
| 2026-06-09 | 12.96x |
| 2026-06-08 | 12.75x |
| 2026-06-05 | 12.79x |
| 2026-06-04 | 12.60x |
| 2026-06-03 | 12.34x |
| 2026-06-02 | 12.39x |
| 2026-06-01 | 12.38x |
| 2026-05-29 | 12.56x |
| 2026-05-28 | 12.50x |
| 2026-05-27 | 12.47x |
| 2026-05-26 | 12.62x |
| 2026-05-22 | 12.78x |
| 2026-05-21 | 12.41x |
| 2026-05-20 | 12.38x |
| 2026-05-19 | 12.44x |
| 2026-05-18 | 12.27x |
| 2026-05-15 | 12.11x |
| 2026-05-14 | 12.24x |
| 2026-05-13 | 12.03x |
| 2026-05-12 | 12.23x |
| 2026-05-11 | 12.19x |
| 2026-05-08 | 12.24x |
| 2026-05-07 | 12.03x |
| 2026-05-06 | 11.91x |
| 2026-05-05 | 17.26x |
| 2026-05-04 | 17.14x |
| 2026-05-01 | 17.16x |
| 2026-04-30 | 17.36x |
| 2026-04-29 | 17.54x |
| 2026-04-28 | 17.57x |
| 2026-04-27 | 17.47x |
| 2026-04-24 | 17.37x |
| 2026-04-23 | 17.54x |
| 2026-04-22 | 17.38x |
| 2026-04-21 | 17.59x |
| 2026-04-20 | 18.13x |
| 2026-04-17 | 18.36x |
| 2026-04-16 | 18.10x |
| 2026-04-15 | 17.85x |
| 2026-04-14 | 17.97x |
| 2026-04-13 | 17.93x |
| 2026-04-10 | 18.02x |
| 2026-04-09 | 18.10x |
| 2026-04-08 | 18.23x |
| 2026-04-07 | 18.02x |
| 2026-04-06 | 18.03x |
| 2026-04-02 | 18.22x |
| 2026-04-01 | 17.86x |
| 2026-03-31 | 17.68x |
| 2026-03-30 | 17.46x |
| 2026-03-27 | 17.59x |
| 2026-03-26 | 17.88x |
| 2026-03-25 | 18.24x |
| 2026-03-24 | 18.35x |
| 2026-03-23 | 18.01x |
| 2026-03-20 | 18.33x |
| 2026-03-19 | 18.58x |
| 2026-03-18 | 18.24x |
| 2026-03-17 | 18.73x |
| 2026-03-16 | 19.30x |
| 2026-03-13 | 19.51x |
| 2026-03-12 | 19.65x |
| 2026-03-11 | 19.53x |
| 2026-03-10 | 19.62x |
| 2026-03-09 | 20.12x |
| 2026-03-06 | 19.95x |
| 2026-03-05 | 19.99x |
| 2026-03-04 | 20.44x |
| 2026-03-03 | 20.61x |
| 2026-03-02 | 20.67x |
| 2026-02-27 | 20.65x |
| 2026-02-26 | 20.36x |
| 2026-02-25 | 20.18x |
| 2026-02-24 | 20.25x |
| 2026-02-23 | 20.33x |
| 2026-02-20 | 20.08x |
| 2026-02-19 | 19.98x |
| 2026-02-18 | 20.04x |
| 2026-02-17 | 20.02x |
| 2026-02-13 | 20.07x |
| 2026-02-12 | 19.57x |
| 2026-02-11 | 20.32x |
| 2026-02-10 | 20.02x |
| 2026-02-09 | 20.19x |
| 2026-02-06 | 19.99x |
| 2026-02-05 | 19.62x |
| 2026-02-04 | 18.49x |
| 2026-02-03 | 20.47x |
| 2026-02-02 | 20.57x |
| 2026-01-30 | 20.34x |
| 2026-01-29 | 19.97x |
| 2026-01-28 | 19.89x |
| 2026-01-27 | 20.18x |
| 2026-01-26 | 20.15x |
| 2026-01-23 | 20.04x |
| 2026-01-22 | 19.99x |
| 2026-01-21 | 19.95x |
| 2026-01-20 | 19.90x |
| 2026-01-16 | 20.12x |
| 2026-01-15 | 20.14x |
| 2026-01-14 | 19.86x |
| 2026-01-13 | 19.65x |
| 2026-01-12 | 19.46x |
| 2026-01-09 | 19.12x |
| 2026-01-08 | 19.12x |
| 2026-01-07 | 19.37x |
| 2026-01-06 | 19.67x |
| 2026-01-05 | 19.39x |
| 2026-01-02 | 19.29x |
| 2025-12-31 | 19.23x |
| 2025-12-30 | 19.35x |
| 2025-12-29 | 19.36x |
| 2025-12-26 | 19.40x |
| 2025-12-24 | 19.34x |
| 2025-12-23 | 19.38x |
| 2025-12-22 | 19.35x |
| 2025-12-19 | 19.39x |
| 2025-12-18 | 19.37x |
| 2025-12-17 | 19.50x |
| 2025-12-16 | 19.43x |
| 2025-12-15 | 19.88x |
| 2025-12-12 | 19.66x |
| 2025-12-11 | 19.58x |
| 2025-12-10 | 19.39x |
| 2025-12-09 | 19.20x |
| 2025-12-08 | 19.23x |
| 2025-12-05 | 19.33x |
| 2025-12-04 | 19.22x |
| 2025-12-03 | 19.10x |
| 2025-12-02 | 19.90x |
| 2025-12-01 | 20.39x |
| 2025-11-28 | 20.85x |
| 2025-11-26 | 20.83x |
| 2025-11-25 | 21.15x |
| 2025-11-24 | 19.61x |
| 2025-11-21 | 19.29x |
| 2025-11-20 | 19.11x |
| 2025-11-19 | 19.05x |
| 2025-11-18 | 19.09x |
| 2025-11-17 | 19.25x |
| 2025-11-14 | 19.11x |
| 2025-11-13 | 19.28x |
| 2025-11-12 | 19.18x |
| 2025-11-11 | 19.26x |
| 2025-11-10 | 19.24x |
| 2025-11-07 | 19.05x |
| 2025-11-06 | 19.02x |
| 2025-11-05 | 18.72x |
| 2025-11-04 | 18.26x |
| 2025-11-03 | 18.08x |
| 2025-10-31 | 17.93x |
| 2025-10-30 | 18.10x |
| 2025-10-29 | 17.71x |
| 2025-10-28 | 17.83x |
| 2025-10-27 | 17.85x |
| 2025-10-24 | 17.68x |
| 2025-10-23 | 17.48x |
| 2025-10-22 | 17.59x |
| 2025-10-21 | 17.49x |
| 2025-10-20 | 17.42x |
| 2025-10-17 | 17.29x |
| 2025-10-16 | 17.04x |
| 2025-10-15 | 17.05x |
| 2025-10-14 | 16.96x |
| 2025-10-13 | 16.92x |
| 2025-10-10 | 16.97x |
| 2025-10-09 | 16.78x |
| 2025-10-08 | 16.61x |
| 2025-10-07 | 16.51x |
| 2025-10-06 | 16.35x |
| 2025-10-03 | 16.23x |
| 2025-10-02 | 16.51x |
| 2025-10-01 | 16.66x |
| 2025-09-30 | 16.70x |
| 2025-09-29 | 16.48x |
| 2025-09-26 | 16.43x |
| 2025-09-25 | 16.03x |
| 2025-09-24 | 16.50x |
| 2025-09-23 | 16.21x |
| 2025-09-22 | 15.55x |
| 2025-09-19 | 15.60x |
| 2025-09-18 | 15.64x |
| 2025-09-17 | 15.56x |
| 2025-09-16 | 15.60x |
| 2025-09-15 | 15.67x |
| 2025-09-12 | 16.21x |
| 2025-09-11 | 16.23x |
| 2025-09-10 | 15.91x |
| 2025-09-09 | 16.03x |
| 2025-09-08 | 15.99x |
| 2025-09-05 | 15.73x |
| 2025-09-04 | 15.74x |
| 2025-09-03 | 15.85x |
| 2025-09-02 | 15.84x |
| 2025-08-29 | 15.68x |
| 2025-08-28 | 15.60x |
| 2025-08-27 | 15.63x |
| 2025-08-26 | 15.59x |
| 2025-08-25 | 15.52x |
| 2025-08-22 | 15.73x |
| 2025-08-21 | 16.25x |
| 2025-08-20 | 16.27x |
| 2025-08-19 | 15.83x |
| 2025-08-18 | 15.62x |
| 2025-08-15 | 15.74x |
| 2025-08-14 | 15.84x |
| 2025-08-13 | 15.65x |
| 2025-08-12 | 15.56x |
| 2025-08-11 | 15.64x |
| 2025-08-08 | 15.37x |
| 2025-08-07 | 15.04x |
| 2025-08-06 | 15.30x |
| 2025-08-05 | 16.93x |
| 2025-08-04 | 17.00x |
| 2025-08-01 | 16.72x |
| 2025-07-31 | 16.60x |
| 2025-07-30 | 16.90x |
| 2025-07-29 | 16.80x |
| 2025-07-28 | 16.61x |
| 2025-07-25 | 16.83x |
| 2025-07-24 | 16.83x |
| 2025-07-23 | 16.99x |
| 2025-07-22 | 16.97x |
| 2025-07-21 | 16.95x |
| 2025-07-18 | 16.96x |
| 2025-07-17 | 17.04x |
| 2025-07-16 | 17.22x |
| 2025-07-15 | 17.05x |
| 2025-07-14 | 17.18x |
| 2025-07-11 | 17.08x |
| 2025-07-10 | 17.20x |
| 2025-07-09 | 17.34x |
| 2025-07-08 | 17.23x |
| 2025-07-07 | 17.47x |
| 2025-07-03 | 17.14x |
| 2025-07-02 | 16.87x |
| 2025-07-01 | 17.09x |
| 2025-06-30 | 17.33x |
| 2025-06-27 | 17.31x |
| 2025-06-26 | 17.16x |
| 2025-06-25 | 16.93x |
| 2025-06-24 | 17.03x |
| 2025-06-23 | 16.97x |
| 2025-06-20 | 17.00x |
| 2025-06-18 | 17.17x |
| 2025-06-17 | 16.98x |
| 2025-06-16 | 16.94x |
| 2025-06-13 | 17.10x |
| 2025-06-12 | 17.08x |
| 2025-06-11 | 16.63x |
| 2025-06-10 | 16.51x |
| 2025-06-09 | 16.49x |
| 2025-06-06 | 16.75x |
| 2025-06-05 | 16.73x |
| 2025-06-04 | 16.76x |
| 2025-06-03 | 16.89x |
| 2025-06-02 | 16.92x |
Showing the most recent 260 of 4,796 data points. The chart above shows the full history.
Related Metrics
About Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Robert Mauch